Literature DB >> 26339799

Fecal lactoferrin, a marker of intestinal inflammation in children with inflammatory bowel disease.

Anna Borkowska1, Anna Liberek2, Grażyna Łuczak1, Agnieszka Jankowska1, Katarzyna Plata-Nazar1, Maria Korzon1, Barbara Kamińska1.   

Abstract

The aim of this study was to analyze the usefulness of fecal lactoferrin in the diagnosis and monitoring of inflammatory bowel disease (IBD) in children. The study included 52 children with IBD (24 with Crohn's disease and 28 with ulcerative colitis) aged between 0.92 and 18 years, and 41 IBD-free controls of similar age. Fecal concentration of lactoferrin was determined with a quantitative immunoenzymatic test. Fecal concentration of lactoferrin in children with IBD was significantly higher than in the controls. The cut-off value of fecal lactoferrin concentration optimally distinguishing between the children with IBD and the controls was identified as 13 μg/g. The sensitivity and specificity of this cut-off value equaled 80.7% and 92.7%, respectively, and its positive and negative prognostic values were 96.8% and 63.3%, respectively. Patients diagnosed with moderate Crohn's disease had significantly higher fecal concentrations of lactoferrin than children with the mild or inactive disease. Similarly, children with moderate ulcerative colitis showed significantly higher fecal concentrations of lactoferrin than individuals with the mild condition. No significant relationship was found between the fecal concentration of lactoferrin and the severity of endoscopic lesions. Patients with IBD and a positive result of fecal occult blood test were characterized by significantly higher concentrations of lactoferrin than the individuals with IBD and a negative result of this test. In conclusion, fecal concentration of lactoferrin seems to be a useful parameter for diagnosis and monitoring of IBD in children.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26339799     DOI: 10.18388/abp.2015_982

Source DB:  PubMed          Journal:  Acta Biochim Pol        ISSN: 0001-527X            Impact factor:   2.149


  7 in total

1.  Optimal Range of Fecal Calprotectin for Predicting Mucosal Healing in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Authors:  Bing-Jie Xiang; Min Jiang; Ming-Jun Sun; Cong Dai
Journal:  Visc Med       Date:  2021-01-21

2.  Comparisons between myeloperoxidase, lactoferrin, calprotectin and lipocalin-2, as fecal biomarkers of intestinal inflammation in malnourished children.

Authors:  Mara de Moura Gondim Prata; A Havt; D T Bolick; R Pinkerton; Aam Lima; R L Guerrant
Journal:  J Transl Sci       Date:  2016-03-25

Review 3.  Update on clinical and research application of fecal biomarkers for gastrointestinal diseases.

Authors:  Imran Siddiqui; Hafsa Majid; Shahab Abid
Journal:  World J Gastrointest Pharmacol Ther       Date:  2017-02-06

Review 4.  Emerging concepts in non-invasive monitoring of Crohn's disease.

Authors:  Wojciech Marlicz; Karolina Skonieczna-Żydecka; Konstantinos John Dabos; Igor Łoniewski; Anastasios Koulaouzidis
Journal:  Therap Adv Gastroenterol       Date:  2018-04-18       Impact factor: 4.409

5.  Mesenteric Adipose-derived Stromal Cells From Crohn's Disease Patients Induce Protective Effects in Colonic Epithelial Cells and Mice With Colitis.

Authors:  Jill M Hoffman; Aristea Sideri; Jonathan J Ruiz; Dimitris Stavrakis; David Q Shih; Jerrold R Turner; Charalabos Pothoulakis; Iordanes Karagiannides
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-02-08

6.  Antimicrobial peptides and the gut microbiome in inflammatory bowel disease.

Authors:  John Gubatan; Derek R Holman; Christopher J Puntasecca; Danielle Polevoi; Samuel Js Rubin; Stephan Rogalla
Journal:  World J Gastroenterol       Date:  2021-11-21       Impact factor: 5.742

7.  A Simple Noninvasive Score Predicts Disease Activity and Deep Remission in Ulcerative Colitis.

Authors:  Amr Shaaban Hanafy; Mohamed Hesham Monir; Hany Abdel Malak; Mohamed Desoky Aiad
Journal:  Inflamm Intest Dis       Date:  2018-07-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.